Christopher R. Holroyd1, Rakhi Seth1, Marwan Bukhari2, Anshuman Malaviya3, Claire
Holmes1, Elizabeth Curtis4, Christopher Chan1, Mohammed A. Yusuf3, Anna Litwic4, 5 …

The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-
manufactured and highly active molecules with possible off-target effects, followed by …

Topic To provide recommendations for the use of anti-tumor necrosis factor α (TNF-α)
biologic agents in patients with ocular inflammatory disorders. Clinical Relevance Ocular …

1.0 Background Psoriasis is a common, chronic inflammatory skin disease which typically
follows a relapsing and remitting course, and is associated with joint disease in …

Paradoxical adverse events (PAEs) have been reported during biological treatment for
chronic immune-mediated diseases. PAEs are defined as the occurrence during biological …

Purpose: Non-infectious uveitis is a leading cause of vision loss in the developed world. The
purpose of this systematic review is to investigate the epidemiology and risk factors of non …

Background Non-infectious uveitis (NIU) is an immune-mediated disease with clinical
symptoms such as eye pain, redness, floaters, and light sensitivity. NIU is one of the leading …

Recognizing and managing comorbidities in psoriatic arthriti... : Current Opinion in
Rheumatology Recognizing and managing comorbidities in psoriatic arthritis : Current …

Biological agents are increasingly used for a rapidly-expanding number of rheumatic and
systemic autoimmune diseases, with a growing number of reports of the paradoxical …

Topic An international, expert-led consensus initiative to develop systematic, evidence-
based recommendations for the treatment of noninfectious uveitis in the era of biologics …